Stanford Medicine Study Uncovers Biomolecular Shifts in 40s and 60s
By
fzliu
A five-star bake. Worth schmearing, sharing, saving.
Summary
A Stanford Medicine study reveals significant biomolecular changes in individuals in their 40s and 60s, impacting molecules and microorganisms.
Key quotes
· 3 pulledMany of our molecules and microorganisms dramatically rise or fall in number during our 40s and 60s.
The abundance of most molecules and microbes do not shift in a gradual, chronological fashion.
Biological aging is anything but constant, according to a new Stanford Medicine study.
You might also wanna read
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
bit.ly·1h ago
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
biozentrum.unibas.ch·1h ago
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
bbc.co.uk·5h ago
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
newscientist.com·6h ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·6h agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·6h ago